BioticsAI secures FDA approval for ultrasound AI copilot

BioticsAI has secured regulatory approval from the FDA (the US Food and Drug Administration) for its artificial intelligence copilot designed to assist with ultrasound imaging. The technology is being developed to help clinicians detect fetal abnormalities, a critical area of medical imaging where misdiagnosis rates remain surprisingly high. The regulatory milestone, which the company gained in January, marks a significant transition for the startup as it moves from the development phase toward clinical deployment.

The company’s path to securing this regulatory clearance began with a highly capital-efficient approach to product development. BioticsAI built an early, functioning version of its ultrasound copilot for under $100,000, a relatively low development cost for the medical device sector. This early prototype allowed the team to gain significant industry visibility and credibility, culminating in the startup winning the TechCrunch Startup Battlefield competition in 2023. Rather than treating regulatory compliance as a late-stage hurdle, the company integrated clinical validation and regulatory strategy directly into its core product development process from the outset, ensuring the technology was built with regulatory requirements in mind.

According to Robhy Bustami, co-founder and CEO of BioticsAI, founders building in the healthcare space cannot just build fast and break things. Bustami emphasizes that success in this highly regulated sector requires integrating regulatory strategy into product development from day one rather than treating it as an afterthought. Navigating these long, complex timelines also presents internal organizational challenges, particularly in keeping a multidisciplinary team motivated when major milestones are years away. To address this, Bustami focused on building a culture of internal alignment across the company’s engineering and clinical teams. “Making sure everyone is completely aligned, even if it’s outside of their technical scope, constantly seeing wins on the R&D side,” Bustami said, was crucial to maintaining momentum throughout the multi-year regulatory process.

Why it matters

BioticsAI’s journey highlights the challenges of building in the healthcare sector, where success requires navigating strict regulatory environments and long timelines rather than moving fast.